For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Harvard Bioscience Inc (NASDAQ: HBIO) closed the day trading at $0.28 down -23.84% from the previous closing price of $0.37. In other words, the price has decreased by -$23.84 from its previous closing price. On the day, 1.39 million shares were traded.
Ratios:
For a better understanding of HBIO, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.26 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 33.07. For the most recent quarter (mrq), Quick Ratio is recorded 0.40 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 3.01 whereas as Long-Term Debt/Eq ratio is at 0.49.
On March 10, 2023, The Benchmark Company Upgraded its rating to Buy which previously was Speculative Buy and also upped its target price recommendation from $3 to $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 13 ’24 when Green James W bought 10,000 shares for $2.91 per share. The transaction valued at 29,100 led to the insider holds 3,111,091 shares of the business.
Green James W bought 20,000 shares of HBIO for $61,400 on Jun 06 ’24. The Chief Executive Officer now owns 3,101,091 shares after completing the transaction at $3.07 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.14 while its Price-to-Book (P/B) ratio in mrq is 0.85.
Stock Price History:
Over the past 52 weeks, HBIO has reached a high of $3.60, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is -32.96%, while the 200-Day Moving Average is calculated to be -83.32%.
Shares Statistics:
A total of 44.21M shares are outstanding, with a floating share count of 37.41M. Insiders hold about 15.39% of the company’s shares, while institutions hold 60.20% stake in the company.
Earnings Estimates
The market rating for Harvard Bioscience Inc (HBIO) is a result of the insights provided by 2.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.01, with high estimates of $0.03 and low estimates of $0.0.
Analysts are recommending an EPS of between $0.05 and $0.02 for the fiscal current year, implying an average EPS of $0.04. EPS for the following year is $0.06, with 2.0 analysts recommending between $0.08 and $0.04.
Revenue Estimates
2 analysts predict $18.75M in revenue for the current quarter. It ranges from a high estimate of $19.5M to a low estimate of $18M. As of the current estimate, Harvard Bioscience Inc’s year-ago sales were $23.1MFor the next quarter, 2 analysts are estimating revenue of $21.5M. There is a high estimate of $21.5M for the next quarter, whereas the lowest estimate is $21.5M.
A total of 2 analysts have provided revenue estimates for HBIO’s current fiscal year. The highest revenue estimate was $87M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $86.5M. In the same quarter a year ago, actual revenue was $94.14MBased on 2 analysts’ estimates, the company’s revenue will be $95.15M in the next fiscal year. The high estimate is $95.8M and the low estimate is $94.5M.
